All News
Can I Use JAK Inhibitors During Pregnancy?
In 2020, the ACR Recommendations on Reproductive Health notably avoided firm guidance on the use of JAK inhibitors (JAKi) during pregnancy stating, "There is no available evidence regarding use or safety of the new small- molecule agents, tofacitinib, baricitinib, and apremilast, during pregnancy."
Read Article
Maui Potpourri (2.13.2026)
Dr. Jack Cush reviews the hot item takeaways from last week's RheumNow.Live 2026.
Read Article
Case-control study of 72 estab. & 56 early RA pts the diagnostic performance of 14-3-3η testing showed AUC ≥0.85 for early & estab.RA. Early RA, -CCP had better specificity (96.4%) and a positive likelihood ratio (21.2%), while 14-3-3η had higher sensitivity (88.1%) https://t.co/jaUux9quy6
Dr. John Cush RheumNow ( View Tweet)
RT @RichardPAConway
ACR/Chest and EULAR/ERS guidelines for RA-ILD presented by Dr Sparks. I'm posting the one I use ;) #RNL26 https://t.co/fwTjB2bIqg
Dr. John Cush RheumNow ( View Tweet)
RT @richardPAConway
Data from Scott Matson's group showing that immunosuppressing RA-ILD (agnostic to agent) results in stabilisation of the previous downward trajectory of pulmonary function tests. #RNL26 https://t.co/TMNeCsPDep
Dr. John Cush RheumNow ( View Tweet)
RT @RichardPAConway
UIP pattern RA-ILD is where the big problem is. We are less good at treating this. Perhaps the newer agents such as nerandomilast will change this? #RNL26 https://t.co/lzKFulaomD
Dr. John Cush RheumNow ( View Tweet)
RT @richardPAConway
Target trial emulation from Dr Sparks group in RA-ILD. Abatatacept and JAKi seem to be better than RTX. TNFi and IL-6i appear similar to RTX. Thought provoking! #RNL26 https://t.co/vmg7ot9m8b
Dr. John Cush RheumNow ( View Tweet)
RT @richardPAConway
Data from Scott Matson's group showing that immunosuppressing RA-ILD (agnostic to agent) results in stabilisation of the previous downward trajectory of pulmonary function tests. #RNL26 https://t.co/MoYoM0K1cs
Dr. John Cush RheumNow ( View Tweet)
RT @richardPAConway
The new kid on the block in RA-ILD (and other PPF). Nerandomilast, an anti-fibrotic with additional anti-inflammatory/immunomodulating functions. Demonstrated significant mortality benefit in ILD. #RNL26 https://t.co/8DU3WyPQGy
Dr. John Cush RheumNow ( View Tweet)
RT @RichardPAConway
ACR/Chest and EULAR/ERS guidelines for RA-ILD presented by Dr Sparks. I'm posting the one I use ;) #RNL26 https://t.co/a6vwQWbjE7
Dr. John Cush RheumNow ( View Tweet)
RT @ericdeinMD
#RNL26
Prosthetic joint infection vs flare?
- PJI risk 50-80% higher in RA (OR 1.47-1.8)
- Immunosuppressants, intra-artic injections, RA activity, BMI incr risk
- Delay in diagnosis https://t.co/XTozafDQyf
Dr. John Cush RheumNow ( View Tweet)
Screening study of lung US (LUS) vs HRCT in 73 RA pts (DAS28 3.47) Chest HRCT identified ILD in 29%. LUS identified ILD in 22% of patients. LUS sensitivity was 59%; specificity 94%. ROC. This study demonstrates the good diagnostic performance of LUS in RA- ILD detection https://t.co/E8avnbvUiw
Dr. John Cush RheumNow ( View Tweet)
RT @ericdeinMD
#RNL26
Inflammatory arthritis pts getting TKA:
- increased risk of RBC transfusion (OR 1.39), infection (1.64) and readmission (1.46)
- THA: also risk of mechanical complications (like dislocation) OR 1.3 https://t.co/ovW2C2EuXF
Dr. John Cush RheumNow ( View Tweet)
RT @RichardPAConway
UIP pattern RA-ILD is where the big problem is. We are less good at treating this. Perhaps the newer agents such as nerandomilast will change this? #RNL26 https://t.co/Z0BXxyNrCI
Dr. John Cush RheumNow ( View Tweet)
RT @RichardPAConway
Comparative survival in incident RA-ILD 1955-1995 vs 1999-2014. We are getting better, althoug need to take into account the general survival improvement also. More work to do! #RNL26 https://t.co/VwV33tHgR8
Dr. John Cush RheumNow ( View Tweet)
RT @ericdeinMD
#RNL26 Haque
Effect of GLP1 on Pts with RA
Retrospective study
Significant reduction is RA disease activity (P=0.03), VAS pain (p<0.001), weight, cholesterol and A1c
But 1/3 stopped due to side effects (mostly GI) https://t.co/SNHTcRFmAX
Dr. John Cush RheumNow ( View Tweet)
RT @richardPAconway
We have improved RA mortality in many areas but respiratory (mainly ILD) and infectious issues remain stubbornly elevated. #RNL26 https://t.co/ViucOIOOzY https://t.co/3kIqPMeKKX
Links:
Dr. John Cush RheumNow ( View Tweet)
RT @richardPAConway
AUC of various published screening strategies for RA-ILD. We often say 0.80 is an acceptable cut off but ideally would like a bit better #RNL26 https://t.co/L19uJ7ETwc
Dr. John Cush RheumNow ( View Tweet)
RT @RichardPAConway
Odds ratios for ILD in early RA from SAIL-RA study. Again disease activity stands out. #RNL26 https://t.co/9cXjOFl3Th
Dr. John Cush RheumNow ( View Tweet)
RT @richardPAconway
Who to screen for RA-ILD is a tricky one. It is not feasible to screen everyone. This is from ACR/Chest 2023 ILD guidelines and is based on identified risk factors. #RNL26 https://t.co/NtAWYCVclJ
Dr. John Cush RheumNow ( View Tweet)
